01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Glaucoma
06.1.1 Understanding the Disease
06.1.2 Types of Glaucoma
06.1.3 Etiology
06.1.4 Signs and Symptoms
06.1.5 Diagnosis
06.1.6 Management
06.1.7 Epidemiology
06.2 Dry Eye Syndrome
06.2.1 Understanding the Disease
06.2.2 Types of Dry Eye Syndrome
06.2.3 Causes of Dry Eye Syndrome
06.2.4 Risk Factors of Dry Eye Syndrome
06.2.5 Signs and Symptoms
06.2.6 Diagnosis
06.2.7 Management
06.3 Diabetic Retinopathy
06.3.1 Understanding the Disease
06.3.2 Etiology
06.3.3 Diagnosis
06.3.4 Classification
06.3.5 Epidemiology
06.3.6 Management
06.4 RVO
06.4.1 Understanding the Disease
06.4.2 Types of RVO
06.4.3 Etiology
06.4.4 Diagnosis
06.4.5 Management
06.5 AMD
06.5.1 Understanding the Disease
06.5.2 Stages of AMD
06.5.3 Types of AMD
06.5.4 Etiology
06.5.5 Signs and Symptoms
06.5.6 Diagnosis
06.5.7 Management
06.6 Macular Edema
06.6.1 Understanding the Disease
06.6.2 Etiology
06.6.3 Diagnosis
06.6.4 Management
06.7 Economic Burden of Ophthalmic Diseases
07. Pipeline Analysis
07.1 Pipeline Portfolio: Glaucoma
07.1.1 Rhopressa
07.1.2 Roclatan
07.1.3 Trabodenoson
07.1.4 Lomerizine HCl
07.1.5 Y-39983
07.2 Pipeline Portfolio: Dry Eye Syndrome
07.2.1 Lifitegrast
07.2.2 OPC-12759E
07.2.3 EBI-005
07.3 Pipeline Portfolio: Diabetic Retinopathy
07.3.1 Squalamine
07.3.2 K-115-R/Ripasudil Hydrochloride Hydrate
07.4 Pipeline Portfolio: AMD
07.4.1 Anecortave Acetate (Suspension)
07.4.2 E10030
07.4.3 Abicipar
07.5 Pipeline Portfolio: RVO
07.5.1 TLC399
07.5.2 AGN208397
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Disease Type
09.1 Global Ophthalmic Therapeutics Market by Disease Type
09.2 Glaucoma
09.3 Dry Eye Syndrome
09.4 Retinal Disorders
09.4.1 Diabetic Retinopathy
09.4.2 Macular Edema
09.4.3 AMD
09.4.4 RVO
09.5 Global Glaucoma Therapeutics Market
09.5.1 Market Size and Forecast
09.6 Global AMD Therapeutics Market
09.6.1 Market Size and Forecast
09.7 Global Macular Edema Therapeutics Market
09.7.1 Market Size and Forecast
09.8 Global Dry Eye Syndrome Therapeutics Market
09.8.1 Market Size and Forecast
09.9 Global Diabetic Retinopathy Therapeutics Market
09.9.1 Market Size and Forecast
09.10 Global RVO Therapeutics Market
09.10.1 Market Size and Forecast
10. Market Segmentation by Route of Administration
10.1 Topical
10.2 Systemic
10.2.1 IV
10.2.2 Oral
10.3 Intravitreal
11. Market Segmentation by Molecule Type
11.1 Biologics
11.2 Small Molecules
12. Market Segmentation by Dosage Form
12.1 Solutions
12.2 Implants
12.3 Pills
13. Geographical Segmentation
13.1 Global Ophthalmic Therapeutics Market by Geography 2014-2019
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and Their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and Their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Novartis
21.2.2 Actavis
21.2.3 F. Hoffmann-La Roche
21.2.4 Regeneron Pharmaceuticals
21.2.5 Bayer
21.2.6 Pfizer
21.2.7 Merck
21.3 Other and Future Prominent Vendors
22. Key Vendor Analysis
22.1 Actavis
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Information
22.1.8 SWOT Analysis
22.2 Bayer
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation by Revenue 2014
22.2.4 Business Segmentation by Revenue 2013 and 2014
22.2.5 Geographical Segmentation by Revenue 2014
22.2.6 Business Strategy
22.2.7 Recent Developments
22.2.8 SWOT Analysis
22.3 F. Hoffmann-La Roche
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Information
22.3.8 SWOT Analysis
22.4 Merck
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation by Revenue 2013
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Developments
22.4.8 SWOT Analysis
22.5 Novartis
22.5.1 Key Facts
22.5.2 Business Description
22.5.3 Business Segmentation
22.5.4 Revenue by Business Segmentation
22.5.5 Revenue Comparison 2012 and 2013
22.5.6 Sales by Geography
22.5.7 Business Strategy
22.5.8 Key Developments
22.5.9 SWOT Analysis
22.6 Pfizer
22.6.1 Key Facts
22.6.2 Business Overview
22.6.3 Business Segmentation by Revenue 2014
22.6.4 Business Segmentation by Revenue 2013 and 2014
22.6.5 Geographical Segmentation by Revenue 2014
22.6.6 Business Strategy
22.6.7 Key developments
22.6.8 SWOT Analysis
22.7 Regeneron Pharmaceuticals
22.7.1 Key Facts
22.7.2 Business Overview
22.7.3 Product Segmentation
22.7.4 Revenue Product Segmentation
22.7.5 Business Strategy
22.7.6 Key Information
22.7.7 SWOT Analysis
23. Other Reports in This Series


List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Major Ophthalmic Conditions
Exhibit 3: Types of Glaucoma
Exhibit 4: Development of Diabetic Retinopathy
Exhibit 5: Classification of Diabetic Retinopathy
Exhibit 6: Types of RVO
Exhibit 7: Types of AMD
Exhibit 8: Global Ophthalmic Therapeutics Market 2014-2019 ($ millions)
Exhibit 9: Global Ophthalmic Therapeutics Market by Disease Type
Exhibit 10: Global Ophthalmic Therapeutics Market by Disease Type 2014
Exhibit 11: Global Glaucoma Therapeutics Market 2014-2019 ($ millions)
Exhibit 12: Key Takeaways: Global Glaucoma Therapeutics Market
Exhibit 13: Global AMD Therapeutics Market 2014-2019 ($ millions)
Exhibit 14: Key Takeaways: Global AMD Therapeutics Market
Exhibit 15: Global Macular Edema Therapeutics Market 2014-2019 ($ millions)
Exhibit 16: Key Takeaways: Global Macular Edema Therapeutics Market
Exhibit 17: Global Dry Eye Syndrome Therapeutics Market 2014-2019 ($ millions)
Exhibit 18: Key Takeaways: Global Dry Eye Syndrome Therapeutics Market
Exhibit 19: Global Diabetic Retinopathy Therapeutics Market 2014-2019 ($ millions)
Exhibit 20: Key Takeaways: Global Diabetic Retinopathy Therapeutics Market
Exhibit 21: Global RVO Therapeutics Market 2014-2019 ($ millions)
Exhibit 22: Key Takeaways: Global RVO Therapeutics Market
Exhibit 23: Global Ophthalmic Therapeutics Market: YoY Growth Rate and Revenue by Disease Type 2014-2019
Exhibit 24: Global Ophthalmic Therapeutics Market by Route of Administration
Exhibit 25: Global Ophthalmic Therapeutics Market by Molecule Type
Exhibit 26: Global Ophthalmic Therapeutics Market by Dosage Form
Exhibit 27: Global Ophthalmic Therapeutics Market by Geography 2014
Exhibit 28: Major Drivers of Global Ophthalmic Therapeutics Market
Exhibit 29: Major Challenges in Global Ophthalmic Therapeutics Market
Exhibit 30: Major Trends in Global Ophthalmic Therapeutics Market
Exhibit 31: Vendor Ranking 2014
Exhibit 32: Novartis: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
Exhibit 33: Actavis: YoY Revenue of Restasis 2012-2014 ($ millions)
Exhibit 34: Actavis: YoY Revenue of Lumigan 2012-2014 ($ millions)
Exhibit 35: Actavis: YoY Revenue of Alphagan, Alphagan P, and Combigan 2012-2014 ($ millions)
Exhibit 36: F. Hoffmann-La Roche: YoY Revenue and Growth Rate of Lucentis 2011-2014 ($ millions)
Exhibit 37: Regeneron Pharmaceuticals: YoY Revenue and Growth Rate of Eylea 2011-2014 ($ millions)
Exhibit 38: Bayer: YoY Revenue and Growth Rate of Eylea 2012-2014 ($ millions)
Exhibit 39: Pfizer: YoY Revenue and Growth Rate of Xalatan/Xalacom 2012-2014 ($ millions)
Exhibit 40: Actavis: Business Segmentation 2013
Exhibit 41: Actavis: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 42: Actavis: Sales by Geography ($ millions)
Exhibit 43: Bayer: Business Segmentation by Revenue 2014
Exhibit 44: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 45: Bayer: Geographical Segmentation by Revenue 2014
Exhibit 46: Business Segmentation of F. Hoffmann-La Roche 2013
Exhibit 47: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 48: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 49: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
Exhibit 50: Merck: Business Segmentation by Revenue 2013
Exhibit 51: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 52: Merck: Sales by Geography 2013
Exhibit 53: Novartis: Business Segmentation
Exhibit 54: Novartis: Revenue by Business Segmentation 2013
Exhibit 55: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 56: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 57: Pfizer: Business Segmentation by Revenue 2014
Exhibit 58: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 59: Pfizer: Geographical Segmentation by Revenue 2014
Exhibit 60: Regeneron Pharmaceuticals: Product Segmentation
Exhibit 61: Regeneron Pharmaceuticals: Revenue Product Segmentation 2013